[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Würschmidt, Florian ^a   Petersen, Cordula ^b   Wahl, Andreas ^a   Dahle, Jörg ^a   Kretschmer, Matthias ^a  

^a Allianz AG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROETHYLCHOLINE;

ADULT; AGED; ARTICLE; BLADDER DISEASE; BONE PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; FATIGUE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEGAVOLTAGE RADIOTHERAPY; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; RECURRENT CANCER; TREATMENT PLANNING; CANCER STAGING; CARCINOMA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; RECURRENT DISEASE; SCINTISCANNING;

AGED; CARCINOMA; CHOLINE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955441259     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-44     Document Type: Article

References (14)

1. Grosu A-L, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005, 181:483-499. 10.1007/s00066-005-1422-7, 16044216.
2. Picchio M, Giovannini E, Crivellaro C, Gianolli L, Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiotherapy and Oncology 2010, 96:347-350. 10.1016/j.radonc.2010.07.016, 20708811.
3. Bolla M, Poppel H, Collette L, Cangh P, Vekemans K, Pozzo L, Reijke TM, Verbaeys A, Bosset JF, Velthoven R, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578. 10.1016/S0140-6736(05)67101-2, 16099293.
4. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED, 8794 S. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007, 25:2225-2229. 10.1200/JCO.2006.09.6495, 17538167.
5. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovò MG. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006, 33:1387-1398. 10.1007/s00259-006-0150-2, 16865395.
6. Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, Reske SN, Mottaghy FM. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009, 27:619-625. 10.1007/s00345-009-0371-7, 19234708.
7. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998, 39:990-995.
8. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJA. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003, 44:32-38. discussion 38-39, 10.1016/S0302-2838(03)00207-0, 12814672.
9. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003, 44:331-335.
10. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007, 99:1415-1420. 10.1111/j.1464-410X.2007.06772.x, 17428249.
11. Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S, Stenzl A. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008, 102:446-451. 10.1111/j.1464-410X.2008.07592.x, 18410442.
12. Niyazi M, Bartenstein P, Belka C, Ganswindt U. Choline PET based dose-painting in prostate cancer--modelling of dose effects. Radiat Oncol 2010, 5:23. 10.1186/1748-717X-5-23, 2848061, 20298546.
13. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, Polascik TJ, Price DT. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001, 61:110-117.
14. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006, 354:496-507. 10.1056/NEJMra050276, 16452561.